Posted by Michael Wonder on 17 Apr 2023
IntelGenx announces FDA approval of Rizafilm for the treatment of acute migraine
17 April 2023 - Partner Gensco Pharma preparing to commercially launch Rizafilm across the United States as soon as is practicable.
IntelGenx today announced that the US FDA has approved the Company’s Rizafilm VersaFilm new drug application for the treatment of acute migraine.
